Clinical Scenarios that Require Suspension of Antiplatelet Therapy in Patients with Ischemic Heart Disease

Main Article Content

Vania Hailed Moreno Mora
Christian Alfonso Torres Bazán

Abstract

Antiplatelet therapy is increasingly common, especially among patients with ischemic heart disease or atrial fibrillation. With the rising number of individuals undergoing anticoagulation treatment, often for conditions like atrial fibrillation, and the increased use of antiplatelet drugs for atherosclerotic disease prevention, the necessity for procedural interventions that require the suspension of these therapies has surged. The decision to interrupt antiplatelet treatment becomes crucial in such scenarios, balancing the risks of thrombotic events and bleeding complications. Implementing appropriate strategies demands a comprehensive understanding of the indications, associated complications, and optimal management of this therapeutic interruption. This review aims to consolidate current knowledge and guidelines, providing insights into the theoretical framework, indications for suspension, potential complications, and practical considerations in managing the suspension of antiplatelet therapy in clinical scenarios related to ischemic heart disease.

Article Details

How to Cite
Vania Hailed Moreno Mora, & Christian Alfonso Torres Bazán. (2023). Clinical Scenarios that Require Suspension of Antiplatelet Therapy in Patients with Ischemic Heart Disease. International Journal of Medical Science and Clinical Research Studies, 3(11), 2829–2831. https://doi.org/10.47191/ijmscrs/v3-i11-54
Section
Articles

References

I. Martinez, K. A., Eckman, M. H., Pappas, M. A., & Rothberg, M. B. (2022). Prescribing of anticoagulation for atrial fibrillation in primary care. Journal of Thrombosis and Thrombolysis, 54(4), 616-624.

II. Zhao, Y. J., Lin, L., Zhou, H. J., Tan, K. T., Chew, A. P., Foo, C. G., ... & Lim, W. S. (2016). Cost-effectiveness modelling of novel oral anticoagulants incorporating real-world elderly patients with atrial fibrillation. International journal of cardiology, 220, 794-801.

III. Mezue, K., Obiagwu, C., John, J., Sharma, A., Yang, F., & Shani, J. (2017). Novel oral anticoagulants in atrial fibrillation: update on apixaban. Current Cardiology Reviews, 13(1), 41-46.

IV. Piccolo, R., Feres, F., Abizaid, A., Gilard, M., Morice, M. C., Hong, M. K., ... & Valgimigli, M. (2017). Risk of early adverse events after clopidogrel discontinuation in patients undergoing short-term dual antiplatelet therapy: an individual participant data analysis. JACC: Cardiovascular Interventions, 10(16), 1621-1630.

V. Gould, M. K., Garcia, D. A., Wren, S. M., Karanicolas, P. J., Arcelus, J. I., Heit, J. A., & Samama, C. M. (2012). Prevention of VTE in nonorthopedic surgical patients: antithrombotic therapy and prevention of thrombosis: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest, 141(2), e227S-e277S.

VI. Kim, H. S., Kang, J., Hwang, D., Han, J. K., Yang, H. M., Kang, H. J., ... & Park, K. W. (2020). Prasugrel-based de-escalation of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (HOST-REDUCE-POLYTECH-ACS): an open-label, multicentre, non-inferiority randomised trial. The Lancet, 396(10257), 1079-1089.

VII. Olesen, J. B., Torp-Pedersen, C., Hansen, M. L., & Lip, G. Y. (2012). The value of the CHA2DS2-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score 0–1: a nationwide cohort study. Thrombosis and haemostasis, 107(06), 1172-1179.

VIII. Fugate, J. E. (2015). Complications of neurosurgery. CONTINUUM: Lifelong Learning in Neurology, 21(5), 1425-1444.

IX. Galli, M., Laborante, R., Andreotti, F., Vergallo, R., Montone, R. A., Iaconelli, A., ... & D’Amario, D. (2022). Bleeding complications in patients undergoing percutaneous coronary intervention. Reviews in Cardiovascular Medicine, 23(8), 286.

X. Veitch, A. M., Vanbiervliet, G., Gershlick, A. H., Boustiere, C., Baglin, T. P., Smith, L. A., ... & Dumonceau, J. M. (2016). Endoscopy in patients on antiplatelet or anticoagulant therapy, including direct oral anticoagulants: British Society of Gastroenterology (BSG) and European Society of Gastrointestinal Endoscopy (ESGE) guidelines. Endoscopy, 48(04), 385-402.

XI. Kleiboer, B., Layer, M. A., Cafuir, L. A., Cuker, A., Escobar, M., Eyster, M. E., ... & Buckner, T. W. (2022). Postoperative bleeding complications in patients with hemophilia undergoing major orthopedic surgery: A prospective multicenter observational study. Journal of thrombosis and haemostasis, 20(4), 857-865.